Skip to main content
Registrieren
Springer Medizin Österreich
SUCHE
MENÜ 1 2 3 4
main-content
nach oben

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2019

16.07.2019 | short review

Post San Antonio: immunotherapy, chemotherapy and new combinations

verfasst von: MD Karl Mayrhofer, MD, MBA Kathrin Strasser-Weippl

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

This article gives a summary of several studies presented at the San Antonio Breast Cancer Symposium in 2018. In specific, the biomarker analysis of the ‘IMpassion130’ trial, the effects of CDK4/6 inhibitors on T-cells and tumor immunogenicity, adjuvant chemotherapy in older patients, the prognostic relevance of achieving a pathologic complete response after neoadjuvant therapy, the quality of life analysis of the ‘TAILORx’ trial, the prognostic impact of detecting bone marrow tumor cells at the time of primary resection and b-cell lymphoma 2 as a new possible therapeutic target in luminal breast cancer, are discussed.
Vorheriger Artikel Post San Antonio Breast Cancer Symposium 2018
Nächster Artikel Cure is not enough! Why it is time to act and close the gap
Literatur
1.
Emens LA, et al. IMpassion130. San Antonio Breast Cancer Symposium; 4.–8. 12. 2018; San Antonio. 2018. Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer. Abstract GS1-04.
2.
Hurvitz S, et al. Abstract PD2-10: Treatment with abemaciclib modulates the immune response in gene expression analysis of the neoMONARCH neoadjuvant study of abemaciclib in postmenopausal women with HR+, HER2 negative breast cancer. In: Poster Discussion Abstracts . American Association for Cancer Research; 2019. S. PD2-10-PD2-10.
3.
Tolaney SM, et al. Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab. J Clin Oncol. 2018;36(15_suppl):1059. CrossRef
4.
Sinha S, et al. Efficacy and utilization trends of adjuvant chemotherapy for stage I, II, and III breast cancer in the elderly population: A National Cancer Database (NCDB) analysis. San Antonio Breast Cancer Symposium; 4.–8. 12. 2018; San Antonio. 2018. Abstract GS2-02.
5.
Hurria A, et al. Development and validation of a chemotherapy toxicity (Chemo Tox) risk score for older patients (Pts) with breast cancer (BC) receiving adjuvant/neoadjuvant treatment (Adjuvant Tx): A R01 and BCRF funded prospective multicenter study. San Antonio Breast Cancer Symposium; 4.–8. 12. 2018; San Antonio. 2018. Abstract GS6-04.
6.
Spring LM, et al. Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality, stratified by breast cancer subtypes and adjuvant chemotherapy usage: Individual patient-level meta-analyses of over 27,000 patients. San Antonio Breast Cancer Symposium; 4.–8. 12. 2018; San Antonio. 2018. Abstract GS2-03.
7.
Geyer CE Jr., et al. Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab. San Antonio Breast Cancer Symposium; 4.–8. 12. 2018; San Antonio. 2018. Primary results from KATHERINE. Abstract GS1-10.
8.
Martín M, et al. Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer. San Antonio Breast Cancer Symposium; 4.–8. 12. 2018; San Antonio. 2018. Abstract GS2-04.
9.
Wagner LI, et al. Symptoms and health-related quality of life on endocrine therapy alone (E) versus chemoendocrine therapy (C+E): TAILORx patient-reported outcomes results. San Antonio Breast Cancer Symposium; 4.–8. 12. 2018; San Antonio. 2018. Abstract GS6-03.
10.
Hartkopf AD, et al. International pooled analysis of the prognostic impact of disseminated tumor cells from the bone marrow in early breast cancer: Results from the PADDY study. San Antonio Breast Cancer Symposium; 4.–8. 12. 2018; San Antonio. 2018. Abstract GS5-07.
11.
Lindeman GJ, et al. A phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax combined with tamoxifen in ER and BCL-2—positive metastatic breast cancer (MBC). San Antonio Breast Cancer Symposium; 4.–8. 12. 2018; San Antonio. 2018. Abstract PD1-06.
Metadaten
Titel
Post San Antonio: immunotherapy, chemotherapy and new combinations
verfasst von
MD Karl Mayrhofer
MD, MBA Kathrin Strasser-Weippl
Publikationsdatum
16.07.2019
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-019-0509-2

Weitere Artikel der Ausgabe 3/2019

memo - Magazine of European Medical Oncology 3/2019 Zur Ausgabe

short review

HIV-triggered lymphoma

short review

Checkpoint inhibitors in head and neck cancer

short review

Update in thrombosis and hemostasis: ASH meeting 2018

short review

Post San Antonio Breast Cancer Symposium 2018

short review

Skin tumours in organ transplant recipients—implications for the plastic surgeon

short review

ASH 2018—Highlights in Multiple Myeloma

Version: 0.2155.0